Skip to main content
. 2021 Mar 29;4:427. doi: 10.1038/s42003-021-01952-2

Fig. 8. Effects of miR199#4 on mdx mice.

Fig. 8

a Grip strength test of mdx mice. Mdx and B10 control mice (8-week-old) were injected twice intravenously with miR199#4 (199#4) and nsCont, and examined by the grip strength test 1 week after the last administration. The first two grip strength data were normalized by body weight and averaged. The number of mice examined was as follows: 13 miR199#4-dosed mdx mice, 12 nsCont-dosed mdx mice, 11 miR199#4-dosed B10 mice, and 13 nsCont-dosed B10 mice. Data are shown as mean ± SEM [*p < 0.05 by Student’s t test (two-tailed)]. b Creatine kinase (CK) activity. 1 week after the first administration, blood samples were collected and serum CK activity was measured. Data are plotted and shown in an arbitrary unit. Meanscore is indicated by a dotted bar [**p < 0.01 by Wilcoxon rank-sum test]. c Cf-miR-1 in the blood. The level of cf-miR-1 was examined in the same blood samples as b by qRT-PCR and analyzed as in Fig. 1a. The data were normalized with the averaged data of nsCont-dosed B10 mice as 1. Data are plotted, and meanscore is indicated by a dotted bar (*p < 0.05 by Wilcoxon rank-sum test). The number of mice examined in b and c was as follows: 10 miR199#4-dosed mdx mice, 9 nsCont-dosed mdx mice, 11 miR199#4-dosed B10 mice, and 11 nsCont-dosed B10 mice.